KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Liabilities and Shareholders Equity (2018 - 2025)

Historic Liabilities and Shareholders Equity for BioNTech SE (BNTX) over the last 8 years, with Q3 2025 value amounting to $24.9 billion.

  • BioNTech SE's Liabilities and Shareholders Equity rose 141.25% to $24.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $95.8 billion, marking a year-over-year decrease of 172.66%. This contributed to the annual value of $24.1 billion for FY2024, which is 274.01% down from last year.
  • Per BioNTech SE's latest filing, its Liabilities and Shareholders Equity stood at $24.9 billion for Q3 2025, which was up 141.25% from $24.5 billion recorded in Q2 2025.
  • Over the past 5 years, BioNTech SE's Liabilities and Shareholders Equity peaked at $24.9 billion during Q3 2025, and registered a low of $5.1 billion during Q1 2021.
  • In the last 5 years, BioNTech SE's Liabilities and Shareholders Equity had a median value of $23.8 billion in 2022 and averaged $21.5 billion.
  • In the last 5 years, BioNTech SE's Liabilities and Shareholders Equity surged by 92756.06% in 2021 and then tumbled by 784.78% in 2025.
  • Quarter analysis of 5 years shows BioNTech SE's Liabilities and Shareholders Equity stood at $18.1 billion in 2021, then soared by 31.15% to $23.8 billion in 2022, then increased by 4.22% to $24.8 billion in 2023, then decreased by 2.74% to $24.1 billion in 2024, then grew by 3.63% to $24.9 billion in 2025.
  • Its Liabilities and Shareholders Equity was $24.9 billion in Q3 2025, compared to $24.5 billion in Q2 2025 and $22.3 billion in Q1 2025.